XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 32.18

-0.4%

12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Olu Emuleomo who started this subject	3/11/2004 8:37:51 PM
From: Robert K.	Read Replies (1) of 17367

Now THis is almost funny. Genentech has some patent rights to use the combination of raptiva and enbril together. I wonder what they are thinking.(but I like it).......vbg >TNF-ALPHA ANTAGONIST AND LFA-1 ANTAGONIST FOR TREATING LFA-1 OR TNF-ALPHA MEDIATED DISORDER Patent Number: WO0143773 Publication date: 2001-06-21 Inventor(s): LEE WYNE PUN (US); TUMAS DANIEL B (US) Applicant(s): GENENTECH INC (US); LEE WYNE PUN (US); TUMAS DANIEL B (US) Requested Patent: AU768324 Application Number: WO2000US33875 20001214 Priority Number(s): US19990170696P 19991214 IPC Classification: A61K39/395; A61K38/17; A61P37/06; A61P29/00; C07K16/28; C07K14/715 EC Classification: C07K16/28B12, A61K39/395C1 Equivalents: AU5439701, CA2394862, EP1237575 Cited patent(s): WO9823761; WO9822137 -------------------------------------------------------------------------------- Abstract -------------------------------------------------------------------------------- The present invention relates to a method for the treating of an LFA-1 mediated disorder or a TNF- alpha mediated disorder by administering effective amounts of an LFA-1 antagonist and a TNF- alpha antagonist. >TIVF-ALPHA ANTAGONIST AND LFA-1 ANTAGONIST FOR TREATING LFA-I OR TNF-ALPHA MEDIATED DISORDER Field of the Invention The present invention relates generally to a method for the treating a lymphocyte function associated (LFA)-t mediated disorder or a tumor necrosis factor (TNF)-a mediated disorder by administering effective amounts of an LFA-I antagonist and a TNF-a antagonist. The invention also relates to treatment of arthritis and psoriasis with an LFA-I antagonist and a TNF-a antagonist.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next